XML 33 R22.htm IDEA: XBRL DOCUMENT v3.8.0.1
Segment Results
9 Months Ended
Sep. 30, 2017
Segment Results [Abstract]  
Segment Results
Note 15. Segment Results

A description of the Company’s three reportable segments, including the specific products manufactured and sold follows below.

In the Industrials segment, the Company designs, manufactures, markets and services a broad range of air compression, vacuum and blower products across a wide array of technologies and applications. Almost every manufacturing and industrial facility, and many service and process industries, use air compression and vacuum products in a variety of applications such as operation of pneumatic air tools, vacuum packaging of food products and aeration of waste water. The Company maintains a leading position in its markets and serves customers globally. The Company offers comprehensive aftermarket parts and an experienced direct and distributor-based service network world-wide to complement all of its products.

In the Energy segment, the Company designs, manufactures, markets and services a diverse range of positive displacement pumps, liquid ring vacuum pumps and compressors, and engineered loading systems and fluid transfer equipment, consumables, and associated aftermarket parts and services. It serves customers in the upstream, midstream, and downstream oil and gas markets, and various other markets including petrochemical processing, power generation, transportation, and general industrial. The Company is one of the largest suppliers in these markets and has long-standing customer relationships. Its positive displacement pumps are used in the oilfield for drilling, hydraulic fracturing, completion and well servicing. Its liquid ring vacuum pumps and compressors are used in many power generation, mining, oil and gas refining and processing, chemical processing and general industrial applications including flare gas and vapor recovery, geothermal gas removal, vacuum de-aeration, enhanced oil recovery, water extraction in mining and paper and chlorine compression in petrochemical operations.  Its engineered loading systems and fluid transfer equipment ensure the safe handling and transfer of crude oil, liquefied natural gas, compressed natural gas, chemicals, and bulk materials.
 
In the Medical segment, the Company designs, manufactures and markets a broad range of highly specialized gas, liquid and precision syringe pumps and compressors primarily for use in the medical, laboratory and biotechnology end markets.  The Company’s customers are mainly medium and large durable medical equipment suppliers that integrate the Company’s products into their final equipment for use in applications such as oxygen therapy, blood dialysis, patient monitoring, wound treatment, and others.  Further, with the recent acquisitions, the Company has expanded into liquid handling components and systems used in biotechnology applications including clinical analysis instrumentation.  The Company also has a broad range of end use deep vacuum products for laboratory science applications.

The Chief Operating Decision Maker (“CODM”) evaluates the performance of its reportable segments based on, among other measures, Segment Adjusted EBITDA.  Management closely monitors the Segment Adjusted EBITDA of each reportable segment to evaluate past performance and actions required to improve profitability.  Inter-segment sales and transfers are not significant.  Administrative expenses related to the Company’s corporate offices and shared service centers in the United States and Europe, which includes transaction processing, accounting and other business support functions, are allocated to the business segments.  Certain administrative expenses, including senior management compensation, treasury, internal audit, tax compliance, certain information technology, and other corporate functions, are not allocated to the business segments.

The following table provides summarized information about the Company’s operations by reportable segment and reconciles Segment Adjusted EBITDA to Income (Loss) Before Income Taxes for the three month and nine month periods ended September 30, 2017 and 2016:
 
  
For the Three
Months Ended
September 30,
  
For the Nine
Months Ended
September 30,
 
  
2017
  
2016 (1)
  
2017
  
2016 (1)
 
             
Revenue
            
Industrials
 
$
288.2
  
$
265.6
  
$
819.0
  
$
803.6
 
Energy
  
301.6
   
137.9
   
719.4
   
385.8
 
Medical
  
59.8
   
59.1
   
172.0
   
172.2
 
Total Revenue
 
$
649.6
  
$
462.6
  
$
1,710.4
  
$
1,361.6
 
Segment Adjusted EBITDA
                
Industrials
 
$
63.1
  
$
55.6
  
$
173.7
  
$
156.2
 
Energy
  
98.6
   
22.0
   
199.2
   
70.2
 
Medical
  
16.8
   
16.6
   
46.9
   
44.7
 
Total Segment Adjusted EBITDA
 
$
178.5
  
$
94.2
  
$
419.8
  
$
271.1
 
Less items to reconcile Segment Adjusted EBITDA to
                
Income (Loss) Before Income Taxes:
                
Corporate expenses not allocated to segments
 
$
13.8
  
$
5.2
  
$
30.9
  
$
18.8
 
Interest expense
  
30.1
   
43.0
   
115.4
   
128.7
 
Depreciation and amortization expense
  
43.5
   
42.9
   
126.9
   
126.9
 
Impairment of goodwill and other intangible assets (a)
  
-
   
-
   
-
   
1.5
 
Sponsor fees and expenses (b)
  
-
   
1.8
   
17.3
   
3.8
 
Restructuring and related business transformation costs (c)
  
6.3
   
18.2
   
20.5
   
46.2
 
Acquisition related expenses and non-cash charges (d)
  
1.2
   
1.9
   
3.1
   
3.6
 
Environmental remediation loss reserve (e)
  
-
   
-
   
0.9
   
-
 
Expenses related to initial stock offering (f)
  
0.5
   
-
   
3.6
   
-
 
Establish public company financial reporting compliance (g)
  
3.8
   
0.1
   
7.2
   
0.1
 
Stock-based compensation (h)
  
9.8
   
-
   
166.0
   
-
 
Loss on extinguishment of debt (i)
  
34.1
   
-
   
84.5
   
-
 
Other adjustments (j)
  
3.0
   
3.2
   
9.8
   
1.8
 
Income (Loss) Before Income Taxes:
 
$
32.4
  
$
(22.1
)
 
$
(166.3
)
 
$
(60.3
)

(1)
In the fourth quarter of fiscal 2016, the Company modified its methodology for presenting reconciling items from Income (Loss) Before Income Taxes.  The reconciling items for the three and nine month periods ended September 30, 2016 have been restated to conform to the methodology used in the three and nine month periods ended September 30, 2017, and included the following:
 
(a)
Represents non-cash charges for impairment of goodwill and other intangible assets.

(b)
Represents management fees and expenses paid to KKR, including a monitoring agreement termination fee of $16.2 million paid in the nine months ended September 30, 2017.

(c)
Restructuring and related business transformation costs consist of the following:

 
 
For the Three
Months Ended
September 30,
  
For the Nine
Months Ended
September 30,
 
 
 
2017
  
2016
  
2017
  
2016
 
 
            
Restructuring charges
 
$
2.8
  
$
3.0
  
$
4.9
  
$
15.4
 
Severance, sign-on, relocation and executive search costs
  
0.6
   
5.7
   
2.2
   
12.7
 
Facility reorganization, relocation and other costs
  
1.0
   
2.9
   
3.9
   
6.5
 
Information technology infrastructure transformation
  
0.8
   
0.6
   
3.4
   
1.0
 
(Gains) losses on asset and business disposals
  
(0.6
)
  
1.7
   
2.0
   
1.6
 
Consultant and other advisor fees
  
0.5
   
3.2
   
1.7
   
6.9
 
Other, net
  
1.2
   
1.1
   
2.4
   
2.1
 
Total restructuring and related business transformation costs
 
$
6.3
  
$
18.2
  
$
20.5
  
$
46.2
 

(d)
Represents costs associated with successful and/or abandoned acquisitions, including third-party expenses, post-closure integration costs and non-cash charges and credits arising from fair value purchase accounting adjustments.

(e)
Represents estimated environmental remediation costs and losses relating to a former production facility.

(f)
Represents expenses related to the Company’s initial stock offering.

(g)
Represents third party expenses to comply with the requirements of Sarbanes-Oxley in 2018 and the accelerated adoption of the new revenue recognition standard (ASC 606 - Revenue from Contracts with Customers) in the first quarter of 2018, one year ahead of the required adoption date for a private company.  These expenses were previously included in ‘Expenses related to initial stock offering’ and prior periods have been restated to conform to current period presentation.

(h)
Represents stock-based compensation expense recognized for stock options outstanding for the three months and nine months ended September 30, 2017 of $7.8 million and $69.2 million, respectively, and DSUs granted to employees at the date of the initial public offering for the three months and nine months ended September 30, 2017 of $2.0 million and $96.8 million, respectively.  See Note 9 “Stock-Based Compensation”.

(i)
Represents losses on extinguishment of debt recognized on the redemption of the senior notes and pay down of a portion of the Original Dollar Term Loan Facility with proceeds from the initial public offering in May 2017($50.4 million) and in connection with the refinancing of the Original Dollar Term Loan Facility and Euro Term Loan Facility in August 2017 ($34.1 million).

(j)
Includes (i) foreign exchange gains and losses, (ii) effects of amortization of prior service costs and amortization of gains in pension and other postretirement benefits (OPEB) expense, (iii) certain legal and compliance costs and (iv) other miscellaneous adjustments.